Biopharma merger and acquisition value for the second quarter of 2022 reached $25.4bn from 36 transactions, 20 of which had disclosed values. Four M&A transactions hit or exceeded the billion-dollar mark during Q2 (see Exhibit 1).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?